J. Lofland

发表

Effects of a Website Designed to Improve the Management of Migraines

C. Sciamanna, M. Manocchia, R. Nicholson, 2006, Headache.

A Review of Health-Related Workplace Productivity Loss Instruments

Kevin D. Frick, L. Pizzi, K. Frick, 2012, PharmacoEconomics.

L. Pizzi, T. Scharf, Doris L Konicki, 2003, Journal of occupational and environmental medicine.

Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis

J. Piercy, V. Joish, P. Anderson, 2021, Dermatology and Therapy.

The value to patients of reducing lesion severity in plaque psoriasis

A. Hauber, J. Lofland, J. González, 2011, The Journal of dermatological treatment.

The Employee Absenteeism Costs of Inflammatory Bowel Disease: Evidence From US National Survey Data

J. Rizzo, C. Gunnarsson, J. Lofland, 2013, Journal of occupational and environmental medicine.

Different Approaches To Valuing the Lost Productivity of Patients with Migraine

K. Frick, J. Lofland, J. Locklear, 2012, PharmacoEconomics.

IMPACT OF MIGRAINE HEADACHE IN THE UNITED STATES

J. Lofland, 2007 .

Migraine Prophylaxis in Managed Care Organizations

J. Lofland, Purna K. Lakhia, 2002 .

Dermatologist–Patient In-Office Discussions of Psoriasis: Focus on Quality of Life

J. Lofland, C. Eagan, Meaghan Onofrey, 2011 .

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream

M. Covington, S. Shepard, S. Yeleswaram, 2021, Pharmaceutics.

Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials.

J. Gagne, S. Silberstein, L. Pizzi, 2006, Journal of occupational and environmental medicine.

Impact of Topiramate Migraine Prophylaxis on Workplace Productivity: Results from Two US Randomized, Double-Blind, Placebo-Controlled, Multicenter Trials

J. Gagne, S. Silberstein, L. Pizzi, 2007 .

Quality‐of‐Life Differences Between Patients With Episodic and Transformed Migraine

W. Young, J. Lofland, D. Meletiche, 2001, Headache.

Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.

D. Nash, A. Batenhorst, N. Johnson, 1999, Archives of internal medicine.

The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey

J. Rizzo, C. Gunnarsson, J. Lofland, 2012, The Journal of dermatological treatment.

Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients’ Perspectives on Shared Decision Making

C. Siegel, J. Lofland, A. Naim, 2016, The Patient - Patient-Centered Outcomes Research.

The Employee Absenteeism Costs of Rheumatoid Arthritis: Evidence From US National Survey Data

J. Rizzo, C. Gunnarsson, J. Lofland, 2015, Journal of occupational and environmental medicine.

Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus

G. Nagy, C. Karyekar, J. Lofland, 2020, Rheumatology.

Economic Evaluation in U.S. Health Care: Principles and Applications

L. Pizzi, J. Lofland, 2005 .

Variations in care: a retrospective database analysis of healthcare utilization patterns for patients with inflammatory bowel disease

G. David, C. Gunnarsson, J. Lofland, 2015, Journal of medical economics.

Systemic Lupus Erythematosus Symptom Clusters and Their Association With Patient‐Reported Outcomes and Treatment: Analysis of Real‐World Data

K. Costenbader, P. Berry, C. Karyekar, 2020, Arthritis care & research.

Prescribing Patterns of Intravenous Golimumab for Rheumatoid Arthritis.

S. Bolge, B. Brady, J. Lofland, 2015, Clinical therapeutics.

Organizational Structure and Educational Components of Pharmacoeconomic Fellowship Programs: A Fellows' Perspective

S. Sansgiry, Z. Khan, V. Maio, 2003 .

The role of the pharmacist in disease management

L. Pizzi, J. Lofland, J. Howell, 2004 .

Original Article Variations in care: a retrospective database analysis of healthcare utilization patterns for patients with inflammatory bowel disease

G. David, C. Gunnarsson, J. Lofland, 2015 .

Health care costs by level of adherence for infliximab patients with crohn’s disease

M. Ingham, J. Lofland, L. Denny, 2014 .

Su1316 Effects of Patient Annual Adherence of Biologics on Healthcare Resource Utilization for Patients With Inflammatory Bowel Disease

G. David, J. Lofland, P. Mallow, 2014 .

P-060 Cost Per Clinical Response, Clinical Remission, and Mucosal Healing of Golimumab Among Patients with Ulcerative Colitis: Results from PURSUIT-Maintenance

J. Rizzo, J. Lofland, P. Mallow, 2013 .

Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review.

C. Ruetsch, J. Lofland, J. Tkacz, 2014, American health & drug benefits.

Stability of infliximab dosing among individuals with Crohnʼs Disease: Results from a mid-atlantic healthplan: P-81.

C. Kassed, L. Nicholls, C. Ruetsch, 2011 .

Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis

J. Rizzo, J. Lofland, P. Mallow, 2013, Journal of medical economics.

Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016

K. Davis, C. Karyekar, J. Lofland, 2021, BMC Research Notes.

Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies

J. Silverberg, V. Joish, S. Sullivan, 2022, American Journal of Clinical Dermatology.

Pharmacy practice and health policy within the U.S.: An introduction and overview

A. Lyles, J. Lofland, 2004 .

Migraine Headache Misconceptions: Barriers to Effective Care

R. Cady, Marcus J. Dortch, J. Lofland, 2004, Pharmacotherapy.

Direct Health Care Insurer and Out-of-Pocket Expenditures of Inflammatory Bowel Disease: Evidence from a US National Survey

J. Rizzo, C. Gunnarsson, J. Lofland, 2012, Digestive Diseases and Sciences.

An Assessment of the AGA and CCFA Quality Indicators in a Sample of Patients Diagnosed with Inflammatory Bowel Disease

C. Ruetsch, B. Brady, J. Lofland, 2015, Journal of managed care & specialty pharmacy.

Workplace Absenteeism and Aspects of Access to Health Care for Individuals With Migraine Headache

K. Frick, J. Lofland, 2006, Headache.

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.

D. Nash, L. Paddock, J. Lofland, 2000, Clinical therapeutics.

Gastroenterologists’ Views of Shared Decision Making for Patients with Inflammatory Bowel Disease

C. Siegel, J. Lofland, A. Naim, 2015, Digestive Diseases and Sciences.

Quality of care measures for migraine: a comprehensive review.

J. Gagne, S. Silberstein, N. Goldfarb, 2007, Disease management : DM.

Measuring Patients' Health-Related Quality of Life: Practical Considerations For Implementing an Outcomes Management Program

J. Lofland, 2002 .

Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine.

D. Nash, A. Batenhorst, R. Cady, 2001, Mayo Clinic proceedings.

Effect of Health Insurance on Workplace Absenteeism in the U.S. Workforce

K. Frick, J. Lofland, 2006, Journal of occupational and environmental medicine.

Adjusting for comorbidities in cost of illness studies

J. Rizzo, C. Gunnarsson, J. Lofland, 2015, Journal of medical economics.

Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs

M. Ingham, J. Lofland, Phaedra T. Johnson, 2017, Patient preference and adherence.

Oral serotonin receptor agonists: a review of their cost effectiveness in migraine.

D. Nash, J. Lofland, 2005, PharmacoEconomics (Auckland).

Thomas Jefferson University, College of Graduate Studies to Offer a Master of Science in Public Health

J. Lofland, M. Koppel, 2002 .

Outcome Measures for Pharmacoeconomics Education

V. Maio, J. Lofland, 2012, PharmacoEconomics.

Effectiveness of Pharmacoeconomic and Outcomes Research Fellowship Programs Within the United States

V. Maio, J. Lofland, 2004 .

RESEARCH ARTICLES Effectiveness of Pharmacoeconomic and Outcomes Research Fellowship Programs Within the United States

V. Maio, J. Lofland, 2004 .

Pharmacoeconomic Fellowships: Preceptors' Views Regarding Adherence to the American College of Clinical Pharmacy Guidelines

D. Nash, V. Maio, J. Lofland, 2003 .

Disease and treatment burden of psoriasis: examining the impact of biologics.

C. Piech, J. Lofland, H. Waters, 2011, Journal of drugs in dermatology : JDD.

Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States

Nan Li, J. Lofland, F. Kariburyo, 2020, Journal of medical economics.

Evaluating Health‐Related Quality of Life: Cost Comparison of Computerized Touch‐Screen Technology and Traditional Paper Systems

N. Goldfarb, J. Lofland, M. Schaffer, 2000, Pharmacotherapy.

Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis.

Chenglong Han, J. Lofland, N. Zhao, 2011, Journal of drugs in dermatology : JDD.

Cyclobenzaprine hydrochloride is a commonly prescribed centrally acting muscle relaxant, which is structurally similar to tricyclic antidepressants (TCAs) and differs from amitriptyline by only one double bond.

J. Lofland, T. Buttaro, D. Szarlej, 2001, The Clinical journal of pain.

Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis

S. Bolge, M. Ingham, J. Lofland, 2017, Patient preference and adherence.

Quality-of-life differences between patients with episodic and transformed migraine.

W. Young, J. Lofland, D. Meletiche, 2000, Headache.

Opioid Use in Patients With Inflammatory Bowel Disease

S. Plevy, C. Marano, J. Lofland, 2020, Crohn's & colitis 360.

Reliability and Validity of the Migraine Therapy Assessment Questionnaire

D. Nash, S. Silberstein, X. Hu, 2002, Headache.

Oral serotonin receptor agonists

D. Nash, J. Lofland, Jennifer H. Lofland, 2012, PharmacoEconomics.

Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016

K. Davis, C. Karyekar, J. Lofland, 2022, BMC research notes.

Mo1362 Geographic Variation in Care of Patients With Inflammatory Bowel Disease Suggests Unequal Quality of Care in the United States

G. David, C. Siegel, C. Gunnarsson, 2013 .

Pharmacoeconomic Fellowships

J. Lofland, Vittorio Maio, Tammy K. Girts, 2012, PharmacoEconomics.

Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients.

J. Lofland, D. Rosmarin, James Piercy, 2024, Dermatology and therapy.